The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer. Source: BioSpace
Life science companies are popular targets for securities fraud litigation. Source: BioSpace
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology…
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions. Source: BioSpace
The proverbial glass ceiling for women in biotech has some cracks but it may not yet have shattered – particularly in the Bay Area hotbed. Source: BioSpace
According to the National Science Foundation (NSF), approximately 42% of life science professionals with doctorate degrees work in academia. Source: BioSpace
Teva Pharmaceuticals will close its offices in Washington, D.C. and New York City as part of the cost-cutting measures. Source: BioSpace
In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug Ozempic (semaglutide). Source: BioSpace
Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration. Source: BioSpace
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan. Source: BioSpace